|
Modified kynureninase enzymes for cancer therapy
This invention describes modified kynureninase enzymes, particularly human enzymes, for degrading kynurenine. These enzymes can be used in compositions and methods for treating cancer by depleting kynurenine levels.
Background
Cancer immunotherapy has emerged as a promising approach to treating a wide range of malignancies. The goal of immunotherapy...
|
|
Improved Human Methylthioadenosine/Adenosine (MTA/ADO) Depleting Enzyme Variants for Cancer Therapy
The technology involves engineered polypeptides (and their compositions, nucleic acids, expression vectors, host cells and methods) that degrade methylthioadenosine and adenosine to treat cancers with MTAP gene deletions. These polypeptides are conjugated with polymers like PEG to enhance their stability and reduce immunogenicity, improving immune...
|
|
Biotechnological platform for engineering enzymes to degrade L‑Cyst(e)ine for cancer therapy
The invention involves engineering a modified enzyme, cystathionine-gamma-lyase, to degrade L-cyst(e)ine, targeting cancer cells reliant on this amino acid. The enzyme exhibits improved stability and reduced immunogenicity, making it suitable for therapeutic applications in cancer treatment.
Background
Cancer cells often exhibit altered metabolic...
|
|
Biotechnological approach for cancer treatment through kynurenine depletion using engineered enzymes
This invention describes engineered kynureninase enzymes that degrade kynurenine, a metabolite linked to cancer progression. These enzymes, optimized for human therapy, can be modified with polyethylene glycol to enhance stability and circulation, offering potential in cancer treatment when combined with other therapies like immunotherapy.
Background
Cancer...
|
|
Enhanced cancer treatment through methionine depletion
The invention involves engineering a modified human cystathionine-γ-lyase enzyme to degrade methionine, an amino acid essential for cancer cell growth. This modified enzyme, with specific amino acid substitutions, offers enhanced catalytic activity, stability, and reduced immunogenicity, making it suitable for cancer treatment by depleting methionine...
|
|
Engineered enzymes for enhanced kynurenine degradation in cancer therapy
The technology describes a modified human kynureninase enzyme with enhanced catalytic efficiency for degrading kynurenine, achieved through specific amino acid substitutions. This enzyme, used in therapeutic applications, reduces kynurenine levels to mitigate tumor-mediated immune suppression and promote anti-tumor immune responses.
Background
Cancer...
|
|
Engineered enzymes for treating cancer and severe combined immunodeficiency
The technology describes engineered methylthioadenosine (MTA) and adenosine (ADO)-degrading enzymes from either prokaryotic or mammalian sources to be used in pharmaceutical formulations to treat cancer or severe combined immunodeficiency (SCID) by enhancing pharmacological properties like serum stability and reducing immunogenicity.
Background
The...
|
|
Therapeutic applications of engineered L-Cyst(e)ine-degrading enzymes
The technology describes engineered primate cystathionine-γ-lyase enzymes with specific amino acid modifications that enhance their ability to degrade L-cyst(e)ine. These enzymes, intended for therapeutic use in cancer and cystinuria, improve stability and reduce immunogenicity.
Background
Cancer and cystinuria present significant therapeutic...
|
|
Pharmacologically optimized human kynureninase variants for cancer treatment
The invention describes a modified kynureninase enzyme with enhanced catalytic efficiency and stability for therapeutic applications, particularly in cancer treatment. It depletes kynurenine, aiding cancer therapy alone or with other treatments, and can be PEGylated for increased in vivo half-life.
Background
Cancer cells often manipulate metabolic...
|
|
Dual-target defense: bispecific antibodies revolutionize pertussis toxin neutralization
Bispecific antibodies target two epitopes on the pertussis toxin protein, enhancing toxin neutralization. Engineered using “knobs-into-holes” technology, they form stable heterodimers, offering similar efficacy to antibody mixtures but with streamlined manufacturing and regulatory benefits.
Background
Pertussis, or whooping cough,...
|
